StockTipsArenaBeta

BUY Marksans Pharma Limited — Anshul Jain, Lakshmishree Investment and Securities

BUYMarksans Pharma Limited
Marksans Pharma share price target & all analyst calls

byAnshul Jain, Lakshmishree Investment and SecuritiesHorizon: NA (inferred Swing (≤2wk))20 May 2026via Business Today

Entry₹210Stated
Target₹245
Total upside +16.67% (call closed)
Stop lossNot given
Exit—No position was opened
ExpiredNA
Follow Anshul Jain for new calls(28% target hit, 29 closed calls)Get alertsWatch MARKSANS for new buy/sell callsGet alertsSee 105 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 5:46 am IST
2 supporting1 neutral0 opposing
Supports the BUY call (2)

Marksans Pharma Limited is acquiring 100% of Netherlands-based QliniQ B.V., expanding its presence in European markets.

NSE · Press Release·1 Jun · 2d ago

(opens in new tab)

Marksans Pharma Limited achieved historic triple: highest Revenue, EBITDA & PAT, delivering on its ₹3,000 Cr Net Income guidance.

NSE · Press Release·26 May · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Marksans Pharma Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company also recommended a final dividend of Rs. 0.90 per equity share.

NSE · Outcome of Board Meeting·26 May · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Marksans Pharma

All analyst calls on Marksans Pharma

More from Anshul Jain, Lakshmishree Investment and Securities

Every call and its outcome